{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:10:48Z","timestamp":1790770248699,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T00:00:00Z","timestamp":1413417600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s40268-014-0065-5","type":"journal-article","created":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T13:52:45Z","timestamp":1413381165000},"page":"265-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol\/Levonorgestrel Combination"],"prefix":"10.1007","volume":"14","author":[{"given":"Doris","family":"Heger-Mahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Dienel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Schl\u00e4fke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Klipping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,16]]},"reference":[{"key":"65_CR1","unstructured":"European directorate for the quality of medicines and healthcare. Lavender oil (Lavandulae aetheroleum). European Pharmacopoeia 5.0. 2005. p. 1894."},{"issue":"6","key":"65_CR2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/YIC.0b013e32833b3242","volume":"25","author":"S Kasper","year":"2010","unstructured":"Kasper S, Gastpar M, M\u00fcller WE, Volz HP, M\u00f6ller HJ, Dienel A, et al. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of \u2018subsyndromal\u2019 anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol. 2010;25(6):277\u201387. doi: 10.1097\/YIC.0b013e32833b3242 .","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"65_CR3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.phymed.2009.10.006","volume":"17","author":"H Woelk","year":"2010","unstructured":"Woelk H, Schl\u00e4fke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine. 2010;17(2):94\u20139.","journal-title":"Phytomedicine"},{"issue":"9","key":"65_CR4","first-page":"1305","volume":"4","author":"WN Setzer","year":"2009","unstructured":"Setzer WN. Essential oils and anxiolytic aromatherapy. Nat Prod Commun. 2009;4(9):1305\u201316.","journal-title":"Nat Prod Commun"},{"issue":"6","key":"65_CR5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617\u201327. doi: 10.1001\/archpsyc.62.6.617 .","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"65_CR6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","volume":"21","author":"HU Wittchen","year":"2011","unstructured":"Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655\u201379. doi: 10.1016\/j.euroneuro.2011.07.018 .","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl B","key":"65_CR7","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/S1550-8579(07)80057-X","volume":"4","author":"MH Bekker","year":"2007","unstructured":"Bekker MH, van Mens-Verhulst J. Anxiety disorders: sex differences in prevalence, degree, and background, but gender-neutral treatment. Gend Med. 2007;4(Suppl B):S178\u201393.","journal-title":"Gend Med"},{"issue":"2","key":"65_CR8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/070674370605100206","volume":"51","author":"JM Somers","year":"2006","unstructured":"Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry. 2006;51(2):100\u201313.","journal-title":"Can J Psychiatry"},{"issue":"11","key":"65_CR9","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1017\/S0033291708003413","volume":"38","author":"KM Scott","year":"2008","unstructured":"Scott KM, Von Korff M, Alonso J, Angermeyer M, Bromet EJ, Bruffaerts R, et al. Age patterns in the prevalence of DSM-IV depressive\/anxiety disorders with and without physical co-morbidity. Psychol Med. 2008;38(11):1659\u201369. doi: 10.1017\/S0033291708003413 .","journal-title":"Psychol Med"},{"issue":"6","key":"65_CR10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2165\/00003088-199018060-00004","volume":"18","author":"DJ Back","year":"1990","unstructured":"Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet. 1990;18(6):472\u201384.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"65_CR11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002018-199309010-00003","volume":"9","author":"GM Shenfield","year":"1993","unstructured":"Shenfield GM. Oral contraceptives. Are drug interactions of clinical significance? Drug Saf. 1993;9(1):21\u201337.","journal-title":"Drug Saf"},{"issue":"1\u20132","key":"65_CR12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1081\/DMR-120001392","volume":"34","author":"S Rendic","year":"2002","unstructured":"Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002;34(1\u20132):83\u2013448. doi: 10.1081\/DMR-120001392 .","journal-title":"Drug Metab Rev"},{"key":"65_CR13","unstructured":"Committee for Proprietary Medical Products. Note for guidance on the investigation of bioavailability and bioequivalence. London: European Agency for the Evaluation of Medicinal Products 2001 (July 26, 2001). Report No.: CPMP\/EWP\/QWP\/1401\/98."},{"key":"65_CR14","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1079\/9781845934132.0859","volume-title":"Botanical medicine in clinical practice","author":"M Thomsen","year":"2008","unstructured":"Thomsen M, Gennat H, Schmidt A. Herb-drug interaction. In: Watson RR, Preedy VR, editors. Botanical medicine in clinical practice. 3rd ed. Wallingford: CABI; 2008. p. 859\u201368.","edition":"3"},{"issue":"5","key":"65_CR15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1124\/dmd.112.050203","volume":"41","author":"O Doroshyenko","year":"2013","unstructured":"Doroshyenko O, Rokitta D, Zadoyan G, Klement S, Schlafke S, Dienel A, et al. Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers. Drug Metab Dispos. 2013;41(5):987\u201393. doi: 10.1124\/dmd.112.050203 .","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"65_CR16","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.104.000794","volume":"32","author":"JA Williams","year":"2004","unstructured":"Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios. Drug Metab Dispos. 2004;32(11):1201\u20138. doi: 10.1124\/dmd.104.000794 .","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"65_CR17","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1017\/S1461145714000017","volume":"17","author":"S Kasper","year":"2014","unstructured":"Kasper S, Gastpar M, M\u00fcller WE, Volz H-P, M\u00f6ller H-J, Schl\u00e4fke S, et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder\u2014a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol. 2014;17(6):859\u201369. doi: 10.1017\/S1461145714000017 .","journal-title":"Int J Neuropsychopharmacol"},{"key":"65_CR18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1472-6904-12-8","volume":"12","author":"PA Kothare","year":"2012","unstructured":"Kothare PA, Seger ME, Northrup J, Mace K, Mitchell MI, Linnebjerg H. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. BMC Clin Pharmacol. 2012;12:8. doi: 10.1186\/1472-6904-12-8 .","journal-title":"BMC Clin Pharmacol"},{"issue":"8","key":"65_CR19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.5414\/CP201675","volume":"50","author":"OJ David","year":"2012","unstructured":"David OJ, Ocwieja M, Meiser K, Emotte C, Jakab A, Wemer J, et al. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results. Int J Clin Pharmacol Ther. 2012;50(8):540\u20134. doi: 10.5414\/CP201675 .","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"65_CR20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0010-7824(93)90025-3","volume":"47","author":"HJ Hoogland","year":"1993","unstructured":"Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception. 1993;47(6):583\u201390.","journal-title":"Contraception"},{"key":"65_CR21","unstructured":"Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. London: European Medicines Agency; 2010. Report No.: CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/ Corr Contract No.: CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/ Corr."},{"issue":"6","key":"65_CR22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.contraception.2012.12.011","volume":"87","author":"FZ Stanczyk","year":"2013","unstructured":"Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17beta-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception. 2013;87(6):706\u201327. doi: 10.1016\/j.contraception.2012.12.011 .","journal-title":"Contraception"},{"issue":"11","key":"65_CR23","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1093\/humrep\/deh493","volume":"19","author":"IJ Duijkers","year":"2004","unstructured":"Duijkers IJ, Klipping C, Verhoeven CH, Dieben TO. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study. Hum Reprod. 2004;19(11):2668\u201373. doi: 10.1093\/humrep\/deh493 .","journal-title":"Hum Reprod"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-014-0065-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-014-0065-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-014-0065-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T06:33:48Z","timestamp":1565937228000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-014-0065-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,16]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["65"],"URL":"https:\/\/doi.org\/10.1007\/s40268-014-0065-5","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,16]]}}}